nature portfolio

Corresponding author(s):	Ya-Ming Hou, Andrei Korostelev
Last updated by author(s):	Jun 24, 2021

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

~ .					
St	· 2	Ť١	IS:	ŀι	C^{ς}

For	For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.				
n/a	Confirmed				
	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement				
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
X	A description of all covariates tested				
X	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>				
\times	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes				
\boxtimes	Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated				
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.				

Software and code

Policy information about availability of computer code

Data collection Data collection was performed using software: SerialEM (vs 3.6), IMOD (vs 4.9.0.). All software is publicly available.

Data collection Data collection

All software used for cryo-EM data analysis has been described in Methods: cisTEM (vs 1.0 beta and pre-release), Frealign v9.11(august 2017 release), RSRef (2000), Phenix (1.18.1), Chimera (vs. 1.14), PyMol (vs 1.8.x), IMOD (vs 4.9.0), EMAN2 (vs 2.3.1), Bsoft (vs 1.9.1). The enzyme-based assays were analyzed using Image J (NIH) version64-bitJava 1.8.0_172. All software is publicly available.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Data analysis

Policy information about <u>availability of data</u>

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The EM density maps generated in this study have been deposited in the EMDB under accession codes EMD-22669 (Structure I); EMD-22670 (Structure II); EMD-22672 (Structure II-FS); EMD-23528 (Structure Irot-FS); EMD-22673 (Structure II-FS); EMD-22674 (Structure III-FS). The atomic coordinates generated in this study have been deposited in the PDB under the accession codes 7K50 (Structure I); 7K51 (Structure II); 7K52 (Structure III); 7K53 (Structure I-FS); 7LV0 (Structure Irot-FS); 7K54 (Structure II-FS); 7K55 (Structure III-FS). For biological and enzyme-based in vitro assays source data are provided with this paper.

Field-specific reporting					
Please select the o	ne below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.				
∑ Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences				
For a reference copy of	the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>				
Life scier	nces study design				
All studies must dis	sclose on these points even when the disclosure is negative.				
Sample size	For biological and enzyme-based in vitro assays, a sample size of 3 was chosen following previously established work to evaluate the standard deviation (SD). If the SD is more than 10% of individual experiments, the sample size would be increased to 5-6, until the SD value drops down to below 10%. Cryo-EM datasets for each complex were collected such that a resolution of ~3.5 A could be reached. Datasets of~ 60,000 - 160,000 particles were sufficient.				
Data exclusions	Micrographs showing ice-contamination or aggregation were excluded from the respective cryo-EM datasets.				
Replication	Replication and reproducibility were measured from the analysis of a sample size of 3. All attempts of replication were successful.				
Randomization	Randomization for biological and enzyme-based in vitro assays is not relevant to this study, because all samples were designed to test a hypothesis and were compared to control samples where key components of the hypothesis were maintained constant. Computational approaches to unbiased particle classification in cryo-EM (maximum likelihood classification) include randomizations. Classifications were repeated multiple times typically by varying number of classes or mask position.				
Blinding	Not applicable for biological and enzyme-based in vitro assays. Blinding was not required in cryo-EM as for each sample the structural data were all analyzed using the same methods.				

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Ma	terials & experimental systems	Methods	
n/a	Involved in the study	n/a Involved in the study	
\boxtimes	Antibodies	ChIP-seq	
\boxtimes	Eukaryotic cell lines	Flow cytometry	
\boxtimes	Palaeontology and archaeology	MRI-based neuroimaging	
\boxtimes	Animals and other organisms	•	
\boxtimes	Human research participants		
\boxtimes	Clinical data		
\boxtimes	Dual use research of concern		